FRESH News: SLAM Used to Fabricate Complex Hydrogel Structures With Gradients

There has been plenty of research on creating 3D printed hydrogels and using them to fabricate functional tissues. Biopolymer hydrogels, with properties that can be tailored and controlled, can be crosslinked to replicate tissue structures, and extrusion-based 3D printing is often used. But, the use of biopolymer hydrogels as 3D printing bioinks is tough, due to issues like low viscosity and trouble controlling microstructure variations. Some researchers have turned to embedded 3D printing methods, but this comes with its own laundry list of problems, such as having difficulty extracting the final product.

UK researchers Jessica J. Senior, Megan E. Cooke, Liam M. Grover, and Alan M. Smith from the University of Huddersfield and University of Birmingham created a method called suspended layer additive manufacturing, or SLAM, that can extrude low viscosity biopolymers into a self‐healing fluid‐gel matrix. The team recently published a paper on their work, titled “Fabrication of Complex Hydrogel Structures Using Suspended Layer Additive Manufacturing (SLAM).” It is worthwhile to note here that FRESH (Freeform Reversible Embedding of Suspended Hydrogels) is a super remarkably similar if not identical technology. So far we’re not getting involved with calling out which term should win here but we are leaning towards using FRESH because it will make it simpler for everyone going forward.

A schematic showing the production of a 3D bioprinted scaffold by use of SLAM.

The abstract states, “There have been a number of recently reported approaches for the manufacture of complex 3D printed cell‐containing hydrogels. Given the fragility of the parts during manufacturing, the most successful approaches use a supportive particulate gel bed and have enabled the production of complex gel structures previously unattainable using other 3D printing methods. The supporting gel bed provides protection to the fragile printed part during the printing process, preventing the structure from collapsing under its own weight prior to crosslinking. Despite the apparent similarity of the particulate beds, the way the particles are manufactured strongly influences how they interact with one another and the part during fabrication, with implications to the quality of the final product. Recently, the process of suspended layer additive manufacture (SLAM) is demonstrated to create a structure that recapitulated the osteochondral region by printing into an agarose particulate gel. The manufacturing process for this gel (the application of shear during gelation) produced a self‐healing gel with rapid recovery of its elastic properties following disruption.”

SLAM works like this: shear cooling a hot agarose solution throughout the sol–gel transition creates the fluid-gel print bed, as fluid gels behave like liquids once stress is applied. Then, the solution is put into a container in order to support the scaffold. Hydrogel and cells are mixed to produce a bioink, which is added to a bioprinter cartridge and extruded into the self-healing, fluid-gel matrix. The bioink is then suspended in its liquid state, and solidification is induced through crosslinking and cell media, which also provides the cell scaffold with metabolites. The construct is released from the supporting gel through low shear washing with deionized water.

The method prevents the initiation of gelation during 3D printing, which allows for great layer integration and “the production of constructs from two or more different materials that have dissimilar physicochemical and mechanical properties,” which creates a part with anisotropic behavior.

“To demonstrate clinical application, we recently created a structure that recapitulated the osteochondral region (the microstructure of which changes across a hard/soft tissue interface) as directed by microcomputed tomography (micro‐CT) imaging to provide accurate dimensions and was tailored to support specific cell phenotypes by controlling the microenvironment,” the researchers explained. “These complex scaffolds feature mechanical gradients that were similar to those found within the ECM and play a crucial role in preventing mechanical failure between interconnecting tissues as well as maintaining cell phenotype.”

The researchers needed to consider the mechanical properties of the fluid-gel print bed during SLAM 3D printing, as “they can impact on construct resolution and complexity.”

“Another embedded printing technique, freeform reversible embedding of suspended hydrogels (FRESH), developed by Hinton et al., uses a gelatin slurry support bath, however the rheological behavior of such material as a suspending agent for 3D bioprinting has not been investigated in depth,” the researchers wrote.

Additionally, they prepared fluid gels at different concentrations of agarose in order to find the best formulation for 3D printing uniform particle sizes, and investigated using needles with differing inner diameters, and a low viscosity dye solution, to find the optimal print resolution.

Optimizing print parameters within agarose fluid gel. A–G) Resolution of bioink printed within fluid bed support using multiple needle diameters and H–J) diffusion of dye through the gel at given time points.

“As the needle inner diameter was increased, the potential resolution decreased. Further, with larger needles, the printable filament thickness was more variable. This is likely due to both more material being extruded and also greater deformation of the fluid‐gel print bed. In very low viscosity solutions of low Mw (molecular weight), diffusion is also a limiting factor for resolution,” the researchers explained.

A) Intricate lattice prior to (left) and following extraction (right) from the bed. B) T7 intervertebral disc as CAD file (left) and lateral (middle) and apical (right) views. C) Intricate bulk structure in the form of a gellan spider. D) Carotid artery as CAD file (left) and during printing (right). D) Tubular structure (left) demonstrating material durability (middle) and perfusibility.

Alginate, collagen, gellan gum, and i‐carrageenan bioinks were used to demonstrate how many complex structures could be made. An intricate lattice structure showed off the scale and complexity that SLAM can achieve, while a T7 intervertebral disc was manufactured to show how the system can print large bulk structures and a spider was an example of 3D printing smaller, more intricate parts.

Several hollow and bifurcating structures, like a carotid artery model and a thick-walled tubular structure, were printed to show how the system can create geometries which are impossible without a 2D collector.

“These structures highlight the capability of this technique for freeform fabrication as large overhanging structures can be printed without the need for additional support structures,” the researchers explained.

The SLAM method can also deposit multiple layers laterally, horizontally, and within “a previously deposited extrude,” which allows constructs to be fabricated with the same biochemical and mechanical gradients that can be found in native tissues. The technique also uses microextrusion to continuously dispense bioinks, which caused better dispensing precision than the use of inkjet printing, and allows for more freedom with cell densities inside the bioink.

“Previous studies have indicated that the use of inkjet printers enables a reduction in print‐induced shear stresses applied to suspended cell populations compared with microextrusion methods, however, there are key features of the supporting bed utilized for SLAM that enable shear minimization utilizing microextrusion,” the researchers wrote.

Due to SLAM’s supporting fluid‐gel bed, low viscosity bioinks can be used – material viscosity can cause shear induction in bioinks, so it’s optimal for fabricating hydrogels.

“Using our system, it has therefore been demonstrated that the issues associated with cell shearing during microextrusion can be easily reduced, achieving admirably low shear stresses on cells that rival those seen during other forms of biofabrication including drop‐on‐demand techniques such as inkjet printing,” the team wrote.

A,B) Bilayer scaffolds using combinations of collagen‐alginate and collagen‐gellan. C) Large collagen‐core gellan‐shell scaffold and D) small collagen‐core alginate‐shell scaffold. E) Schematic of diagram showing control of cell behavior with attachment motif bearing complexes in the upper collagen gel and no attachment motifs for cell suspension within an alginate gel. F) Micro‐CT showing gradient porosity within a lyophilized collagen‐alginate scaffold. G) Confocal micrographs of Hoechst/actin cell staining of HDFs attached in the collagen layer and suspended in the alginate regions of a dual layer scaffold. H) Stress versus showing variations in gel strength and elasticity across a collagen‐alginate scaffold.

The SLAM method can also incorporate multiple biopolymer hydrogels into a single structure, which is important to “satisfy the mechanical, chemical, and biological variations that occur throughout native tissue.” The researchers demonstrated this capability by 3D printing an osteochondral construct, with ex vivo chondrocytes deposited into a gellan gum layer and osteoblasts into one of gellan‐hydroxyapatite. But they went even further, and used SLAM to 3D print integrated structures with different chemistries and gelatin mechanisms.

“Ionotropically gelled (alginate, gellan, and ι‐carrageenan) and thermally gelled (collagen) biopolymers were successfully integrated to form interfacing, dual‐phase scaffolds,” the researchers wrote.

The materials blended enough that mechanical failure did not occur – an environment that closely mimics the native tissue environment.

“Furthermore, this technique of printing integrated layered structures is not only compliant to printing different materials layer upon layer, but also deposition of a second material into the center of another. For example, in addition to producing layered constructs, it was possible to create 3D printed core–shell structures comprising a cylindrical core of collagen encapsulated within a gellan or alginate cylinder with various dimensions,” they continued.

“Another advantage of being able to deposit scaffold material precisely is that cell behavior can be spatially manipulated. Polymers such as collagens that are saturated with integrin binding domains allow cell attachment to the scaffold, whereas alginate and gellan do not naturally possess cell attachment motifs and instead, encapsulate cells with minimum attachment to the surrounding material.”

To learn more about the team’s use of SLAM to 3D print multilayer gradient scaffolds, I suggest you read the paper – they can explain it far better.

“In summary, we have demonstrated that the SLAM technique can be used to overcome the problems associated with using low viscosity bioinks in extrusion‐based bioprinting,” the researchers concluded. “The method enabled the successful fabrication of bulk, intricate, dual phase, and phase‐encapsulated hydrogels from a variety of biopolymer materials that are currently widely investigated in regenerative medicine. Furthermore, it was shown that controlled spatial gradients in mechanical and chemical properties can be produced throughout a single part with interface integrity between different materials. This allows for physicochemical properties of the structure to be designed accordingly with the ability to control porosity, mechanical gradients, cell distribution, and morphology.”

Discuss this and other 3D printing topics at 3DPrintBoard.com or share your thoughts below.

The post FRESH News: SLAM Used to Fabricate Complex Hydrogel Structures With Gradients appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

LulzBot Releases It’s First Bioprinter

Bioprinting is revolutionizing the way 3D printed tissues can be used to mimic in vivo conditions. The fields of regenerative medicine, pharmaceutical development, and cosmetic testing are benefiting from this technological disruption, enabling researchers and companies to better predict efficacy and toxicology of potential drugs early on in the drug discovery process. But it’s no wonder this technology is so enticing, since bringing a new drug to market, with current methods, could cost $350 million dollars and can take more than a decade from start to finish. On the North American front, Colorado-based manufacturer Aleph Objects, the developer behind the LulzBot 3D Printers, announced today a new open-source bioprinter: the LulzBot Bio.

After almost ten years of manufacturing 3D printers, LulzBot finally decided to move into the bioprinting market. The new machine, which is now available for pre-order on the site and will begin shipping in November, enables 3D printing with materials such as unmodified collagen, bioinks, and other soft materials, and is the company’s first-ever Fluid Deposition Fabrication (FDF) 3D printer. FDF is a newfangled name for the FRESH process which we wrote about here and here.  According to LulzBot, unlike its pneumatic counterparts, the Bio’s syringe pump system allows for precise stopping and retraction, preventing unintentional extrusion and stringing while printing intricate models, like vasculature.

The new LulzBot Bio

The printer has a Free Software design that removes proprietary restrictions, providing, what the company considers, a versatile platform for innovation that grows with everchanging discoveries and advancements. LulzBot reports a commitment to freedom of design in general, developing machines that come with freely licensed designs, and specifications, allowing for modifications and improvements to both software and hardware. In this respect, they have partnered with organizations, such as the Open Source Hardware Association, Free Software, and Libre Innovation. The Bio’s free software and open hardware design give researchers the ability to innovate together, letting the machine be easily adjusted for new materials and processes.

“For researchers, you don’t know what materials or processes you’ll be using in six months, let alone one year from now, so you need hardware that can be adjusted quickly and easily, without proprietary restrictions,” said Grant Flaharty, CEO and President of Aleph Objects.

The LulzBot Bio touchscreen for easy control

The LulzBot Bio comes with nearly everything needed to start bioprinting right away, including extensively tested, preconfigured material profiles in Cura LulzBot Edition, the recommended software for the LulzBot printers; Petri dishes; Life Support gel (by FluidForm); alginate, and tools. It also enables printing with unmodified collagen, something that has proven extremely difficult and is considered one of the most promising materials for bioprinting applications, since it is the human body’s major structural protein and is prominent in biological structures.

Actually, printing with unmodified collagen is currently done using the FRESH method, short for Freeform Reversible Embedding of Suspended Hydrogels, which was developed and refined by the Regenerative Biomaterials and Therapeutics Group at Carnegie Mellon University, in Pittsburgh. The LulzBot Bio is actually FRESH-certified, which means it uses thermoreversible support gels to hold soft materials during printing. Then, the temporary support gel is then dissolved, leaving the print intact.

“Other bioprinting techniques often require materials to be chemically altered or mixed with other materials to make them 3D printable,” explained Steven Abadie, CTO of Aleph Objects. “Because of the excellent biocompatibility of collagen, being able to 3D print with it in its original form brings us that much closer to recreating models that mimic human physiology.”

As stated by the company, the LulzBot Bio has already been instrumental in 3D printing some of the first-ever fully functional human heart tissue. This was achieved by a team of researchers at Carnegie Mellon, led by Adam Feinberg, that used the new device to 3D print heart tissue containing collagen and producing parts of the heart at various scales, from capillaries to the full organ.

“What we’ve shown is that we can print pieces of the heart out of cells and collagen into parts that truly function, like a heart valve or a small beating ventricle. By using MRI data of a human heart, we were able to accurately reproduce patient-specific anatomical structure and 3D bioprint collagen and human heart cells,” inidcated Adam Feinberg, principal investigator of the Regenerative Biomaterials and Therapeutics Group at Carnegie Mellon and co-founder of FluidForm.

FluidForm, powered by Carnegie’s research, has been working on the science behind the FRESH technology for quite some time. Now, Aleph Objects has taken the concept straight to the hardware, manufacturing this new machine, which they expect will be the first step to open up bioprinting to the broader market for exponential innovation.

Last June, LulzBot had already announced its collaboration with FluidForm, to combine their expertise and offer new bioprinting solutions. The LulzBot Bio has also been used by Newell Washburn, professor of biomedical engineering and chemistry at Carnegie, and a team of his colleagues to demonstrate how a new machine-learning algorithm could optimize high quality, soft material 3D prints.

According to company execs, the LulzBot Bio will satisfy the needs of many industries, for example, biotechnology, pharmaceuticals, cosmetics, medical devices, and life sciences. It could be ideal for producing bioprinted tissue for pre-clinical testing or used to recreate physiology to study diseases. It certainly seems like a great start to a new printer and perhaps the beginning of the company’s immersion in the bioprinting world.

[Images: LulzBot]

The post LulzBot Releases It’s First Bioprinter appeared first on 3DPrint.com | The Voice of 3D Printing / Additive Manufacturing.

Aleph Objects enters 3D bioprinting with Fluidform, hardware coming summer 2019

Aleph Objects, the manufacturer of LulzBot open source 3D printers, has confirmed its entry into the 3D bioprinting market. In partnership with Massachusetts based 3D bioprinting technology developer FluidForm, Aleph plans to launch LulzBot Bio hardware later this year. For Grant Flaharty, Aleph Objects CEO and President, this undertaking presents a chance for LulzBot to […]